Inspire Investing LLC Sells 27,522 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Inspire Investing LLC decreased its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 38.9% in the fourth quarter, Holdings Channel reports. The fund owned 43,151 shares of the biopharmaceutical company’s stock after selling 27,522 shares during the period. Inspire Investing LLC’s holdings in Amicus Therapeutics were worth $406,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently made changes to their positions in FOLD. Wellington Management Group LLP raised its stake in Amicus Therapeutics by 13.5% during the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock valued at $255,936,000 after purchasing an additional 2,856,101 shares during the last quarter. Millennium Management LLC raised its position in shares of Amicus Therapeutics by 1,758.9% during the second quarter. Millennium Management LLC now owns 1,894,176 shares of the biopharmaceutical company’s stock valued at $18,790,000 after buying an additional 1,792,277 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Amicus Therapeutics during the third quarter valued at about $13,530,000. Assenagon Asset Management S.A. lifted its stake in shares of Amicus Therapeutics by 141.1% in the third quarter. Assenagon Asset Management S.A. now owns 2,037,896 shares of the biopharmaceutical company’s stock valued at $21,765,000 after buying an additional 1,192,489 shares during the period. Finally, Squarepoint Ops LLC grew its position in Amicus Therapeutics by 159.1% during the second quarter. Squarepoint Ops LLC now owns 650,555 shares of the biopharmaceutical company’s stock worth $6,454,000 after buying an additional 399,449 shares in the last quarter.

Insider Transactions at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total value of $75,150.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares in the company, valued at approximately $8,884,273.08. The trade was a 0.84 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold 22,901 shares of company stock valued at $259,863 in the last three months. 2.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have commented on FOLD shares. JPMorgan Chase & Co. raised their price objective on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Morgan Stanley reiterated an “equal weight” rating and set a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. StockNews.com lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Monday, January 13th. Finally, Bank of America upped their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, October 17th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Amicus Therapeutics has an average rating of “Moderate Buy” and an average price target of $16.88.

Amicus Therapeutics Price Performance

Shares of Amicus Therapeutics stock opened at $9.61 on Friday. The stock has a market capitalization of $2.87 billion, a price-to-earnings ratio of -28.26, a P/E/G ratio of 1.53 and a beta of 0.62. The firm’s 50-day moving average price is $9.63 and its two-hundred day moving average price is $10.51. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18. Amicus Therapeutics, Inc. has a 1-year low of $8.78 and a 1-year high of $14.03.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.